INTRODUCTION
The steroid receptors including estrogen, progesterone (ER and PR, respectively), and androgen receptors comprise a subfamily of the larger nuclear receptor superfamily of transcription regulators. The receptors contain discrete functional domains for hormone binding, transactivation, and DNA binding [DNA binding domain (DBD)]. The DBD contains two structurally and functionally essential Cys 4 zinc-finger motifs.
The critical role of the steroid receptors, along with their activating hormones, in normal development and in pathologies such as osteoporosis and breast, uterine, and prostate cancer has led to the development of receptorbased therapies (1, 2) . These therapies depend on agents such as raloxifene and tamoxifen that exert their activities by binding in the hormone binding pockets of the steroid receptors. Very recently, proof-of-principle was provided for a new class of potential breast cancer therapeutic agents that disrupt the binding of ER to estrogen response elements (EREs) by modifying the zinc fingers of the ER DBD (3) . Further interest in the binding of steroid receptors to their DNA target sites has been stimulated by recent work emphasizing the role of naturally occurring imperfect EREs and progesterone/glucocorticoid response elements (PREs/GREs) in modulating the activity of steroid receptors (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Therefore, there is strong interest in developing new ways to both analyze the interaction of steroid receptors with their response elements and to screen large libraries for compounds that target receptor-DNA interactions.
The electrophoretic mobility shift assay (EMSA) is the most widely used technique for the analysis of steroid/ nuclear receptor:hormone response element (HRE) interactions. However, EMSA is slow and laborious, is not a true equilibrium method, uses radioisotopes, and does not provide realtime data. In pioneering work, Boyer et al. (15) and Ozers et al. (16) described the application of fluorescence anisotropy to ER:ERE interactions. In this assay, when polarized light is used to excite a free fluorophor-labeled oligonucleotide, the rapid rotational diffusion of the oligonucleotide results in depolarized emitted light. However, protein binding greatly reduces the mobility of the oligonucleotide, resulting in more polarized emitted light. Thus, protein:DNA interaction is observed as a change in fluorescence anisotropy. Although fluorescence anisotropy and fluorescence polarization are both expressions of the same phenomenon, we used fluorescence anisotrophy in our studies because the values are easier to manipulate. The fluorescence anisotropy assay is performed in solution and provides true equilibrium analysis, real-time kinetic data, and a reduced sensitivity to artifacts of quenching and exogenous fluorescence. However, the previously described assay (15, 16) spread use because it only assays samples one at a time and uses large sample volumes, necessitating the use of very large quantities of receptor. We describe a simple and rapid method for the fluorescence anisotropy-based analysis of steroid receptor:DNA interactions in ultra low-volume 96-well microplates and in 384-well microplates. The fluorescence anisotropy microplate assay (FAMA) we developed should find wide application because it features small reaction volumes and a multiwell microplate platform that provides for maximal use of scarce receptor protein and facile comparison of different binding conditions. The FAMA can also be used to study the interaction of the ER-ERE complex with receptor-associated proteins.
Although fluorescence anisotropy has been widely used for over 70 years, it was the development of sensitive instruments capable of fluorescence anisotropy measurements from samples in microplates in the late 1990s that stimulated the application of fluorescence anisotropy to high-throughput screening (HTS; . To develop the FAMA for HTS, we adapted the FAMA to 384-well microplates and demonstrated well-to-well reproducibility, insensitivity to inhibition by dimethyl sulfoxide (DMSO), ethanol and methanol, and stability of the anisotropy signal for more than 4 hours. The FAMA represents the first system suitable for HTS of large compound libraries to identify a new class of therapeutic agents that act by modulating steroid receptor:DNA interactions (1, 2) . To validate the use of FAMA in screening, we began with a known inhibitor, the zinc chelator, 1,10-phenanthroline (21) . We then screened several less studied zinc chelators to evaluate their abilities to inhibit binding of ERα, ERβ, and human progesterone receptor-B (hPR-B) to their respective response elements. We found that PR: PRE interactions were more sensitive to inhibition than ER:ERE interactions.
MATERIALS AND METHODS

Proteins
Full-length FLAG ® -epitope-tagged human ERα (fhERα) or fhERβ was expressed, in the presence of 200 nM 17β-estradiol (E 2 ), and purified, in the presence of 20 nM E 2 , essentially as we previously described (22, 23) .The purity of the fhERα was greater than 90% using the Silver Stain Plus kit (Bio-Rad Laboratories, Hercules, CA, USA). ER concentration was determined by Western blot analysis with an α-FLAG M2Ab (Sigma, St. Louis, MO, USA) and comparison with a standard curve of unliganded, purified fhERα, whose concentration was previously determined by a 3 H-E 2 (tritiated estradiol) binding assay. Full-length R5020-liganded human progesterone receptor hPR-B was purified as previously described (24) . ERα antibodies ER-Ab1 and ER-Ab10 were from Lab Vision (Fremont, CA, USA). 
Oligonucleotides
Sense strand oligonucleotides (Table  1) were synthesized with fluorescein (6-FAM) at their 5′ ends using phosphoramidite chemistry and PolyPak™ II (Glen Research, Sterling, VA, USA)-purified by the Biotechnology Center (University of Illinois, Urbana, IL, USA). Oligonucleotide concentrations were calculated from A 260 and the degree of fluorescence incorporation (FI) was calculated by the method of Ozers et al. (16) . The FI ratios for all labeled oligonucleotides were approximately 60%. The labeled sense strands were annealed with equimolar amounts of unlabeled antisense strands. Unlabeled competitor oligonucleotides cPRE/GRE, RANDOM, and a 39-nucleotide long concensus ERE (cERE; see Table 1 ) oligonucleotide were also annealed. The ERE sequences in the oligonucleotides used for EMSA were the same as the DNA sequences of the fluorescence probes (A. Krieg, 2003 . Ph.D. thesis, University of Ilinois).
Electrophoretic Mobility Shift Assays
EMSA was carried out as we recently described (22) . Free probe and protein-DNA complexes were quantitated using a Storm ® 840 Gel and Blot Imaging System and ImageQuant™ 5.0 (both from Molecular Dynamics, Sunnyvale, CA, USA). The percent of DNA bound was calculated as: [(protein:DNA counts)/((protein:DNA counts) + (free probe counts))]*100.
Fluorescence Anisotropy Assays
Fluorescein-labeled oligonucleotides for ER assays were diluted to Screening experiments used amounts of fhERα, fhERβ, and hPR-B required to achieve 70%-80% binding of probe in the ER LSAB or the PR anisotropy buffer. The receptor proteins were incubated with either the solvent or compounds for 30 min at room temperature before the addition of the fluorescein-labeled oligonucleotides. The 1,10-phenanthroline-mediated inhibition of ERα:cERE binding was blocked by pre-incubating 1,10-phenanthroline with the indicated amount of ZnCl 2 at 4°C for 10 min before exposure to ERα.
RESULTS
In preliminary studies, we identified conditions for a fluorescence anisotropy assay of steroid receptor binding to HREs amenable to low reaction volumes and a microplate format. To test the FAMA, we analyzed binding of increasing amounts of hERα to the cERE in a 20-μL reaction in an ultra lowvolume 96-well microplate using the high salt buffer. We initially chose 150 mM KCl because it is physiologically relevant and because previous reports and our initial studies suggest that this is the minimum salt concentration needed for sequence-specific binding of hERα to the cERE without the addition of nonspecific competitor DNA. A robust hERα:cERE binding curve with a K d of approximately 5.4 nM was obtained ( Figure 1A) . To demonstrate the flexibility of the assay and to analyze binding under conditions similar to those previously used in EMSA, we also analyzed binding of hERα to the cERE in the low salt buffer that contains poly dI:dC as nonspecific competitor (to reduce non-sequencespecific binding of ERα to the fluorescent cERE probe) and BSA ( Figure 1A) . The K d of approximately 4.7 nM was similar to that observed with the HSAB (Figure 1A) . Although the added BSA increased the fluorescent ERE background, it did not affect the anisotropy change or the K d value. To test the utility of FAMA with lower affinity, naturally occurring, imperfect EREs and to compare data obtained with the FAMA to data obtained using EMSA, we analyzed binding to the cERE, the widely studied imperfect ERE in the pS2 gene and the quite different estrogen responsive unit (ERU) in the proteinase inhibitor-9 gene (Table 1 Figure 1B) . To test for specificity in the binding of hERα to the different EREs in our FAMA assay, we performed competition experiments. A 20-fold molar excess of unlabeled cERE was able to effectively compete with all 3 of the fluorescent ERE probes for binding to hERα, while even a 50-fold excess of random oligonucleotide did not compete for binding ( Figure 1C ). The overall anisotropy change for the lower affinity hERα-ERU binding is more than 3-fold lower (see Figure 1C legend) ; therefore, the anisotropy change is more sensitive to signal variation and more prone to large measurement errors.
We used competition experiments to test the ability of the FAMA to distinguish between nonspecific and sequence-specific binding to DNA. The affinity of steroid receptors for nonspecific DNA is too low for nonspecific interactions to be studied using standard EMSA. Differentiating between these modes of interaction is potentially important in determining how steroid receptors locate and bind to HREs in the presence of a large excess of nonspecific chromosomal DNA. In initial studies, we found that using the low salt buffer without poly dI:dC, hERα bound efficiently to the cPRE/GRE (which differs by two nucleotides per half site from the cERE) as well as to the cERE (data not shown). Because previous studies have shown that hERα exhibits negligible binding and transactivation with the cPRE/GRE in vivo, this interaction probably represents non-sequencespecific binding of hERα to the cPRE/ GRE. To test this hypothesis, we bound hERα to the labeled cERE and to the cPRE/GRE in the LSAB without added poly dI:dC and in the presence of a 20-or 50-fold molar excess of unlabeled cERE or the nonspecific RANDOM oligonucleotide. Both the unlabeled cERE and RANDOM oligonucleotide effectively competed off hERα binding to the cPRE/GRE (Figure 1D ), but only the unlabeled cERE was effective at competing off hERα binding to the fluorescent cERE probe. Because these experiments were done in the low salt buffer without poly dI:dC, hERα binding to the cERE includes a low level of non-sequence-specific binding and a much higher level of sequence-specific binding to the cERE. The slight decline in anisotropy we observe in the low salt buffer without poly dI:dC is due to this nonspecific binding being competed away by the RANDOM oligonucleotide. In contrast, in the low salt buffer with poly dI:dC, the proportion of hERα nonspecifically bound to the ERE, is negligible, and the RANDOM oligonucleotide does not reduce binding of hERα to the cERE (compare Figure 1C with Figure 1D ).
Because it has been suggested that accessory proteins present in cell extracts modify binding of ERα to the cERE, it may occasionally be advantageous to employ cell extracts (23) . Cell extracts also eliminate the need to purify the receptor. Consequently, we tested the ability of the FAMA to measure hERα binding to the cERE in crude cell extracts. A low nonsaturable level of binding to the cERE was observed for the control cell extract from uninfected insect cells, while the expected saturable binding curve was obtained for the extract containing hERα from baculovirus-infected insect cells (Figure 2A ).
While these studies demonstrated the utility of FAMA for analyzing binding of hERα to EREs, we wanted to determine whether the assay was suitable for more general use with steroid receptors. ER also exists as a second isoform, the approximately 55 kDa hERβ, with a different tissue distribution, and likely, different functions than the approximately 66 kDa hERα (27) . Previous studies suggested that hERβ exhibits lower affinity binding to the cERE than hERα (28 Figure 2B ), an affinity for the cERE only slightly lower than is exhibited by hERα.
To test the versatility of FAMA, we analyzed binding of a different steroid receptor, hPR-B, to its recognition sequence, the cPRE/GRE. We generated a highquality saturated binding curve with an approximate K d of 7.4 nM ( Figure  2C ). Because a 50-fold molar excess of 
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cPRE/GRE effectively competed away binding to the fluorescent cPRE/GRE probe and a 50-fold excess of the RAN-DOM oligonucleotide did not compete, binding of hPR-B to the cPRE/GRE was sequence-specific ( Figure 2D ). These studies demonstrate that the FAMA has broad utility for analyzing interaction of steroid receptors with their HREs. The change in anisotropy observed for hPR-B:cPRE/GRE binding is approximately 3-fold greater than we observed with hERα:cERE binding (compare Figure 1A and Figure 2C) . Because hPR-B has a much higher molecular weight than ER (approximately 120 kDa for PR vs. approximately 66 kDa for hERα), the larger protein-DNA complex formed should result in slower rotational diffusion of the complex, and consequently, a larger change in anisotropy.
The enhanced anisotropy change with the larger PREhPR-B complex suggests using the FAMA assay to look at interactions of the ER:ERE complex with the p160 family of steroid receptor coactivators (29) . Previous ERα-p160 coactivator interaction studies employed fluorescent coactivator fragments or peptides, without including ERE interactions (30, 31) . To begin to address the possibility of looking directly at interactions of the ERE-ERα complex with unlabeled coactivators, we analyzed interactions of the hERα: cERE complex with anti-ER antibodies whose molecular weight of approximately 150 kDa is similar to those of the p160 coactivators. The addition of increasing amounts of the antibodies ER Ab-10 and ER Ab-1 to a saturated ERα-cERE complex increased the anisotropy change by up to 1.8-and 1.6-fold, respectively. Equivalent amounts of a control IgG had no effect on the anisotropy change (Figure 3) .
Screening compound libraries to identify potential breast cancer therapeutic agents that work by disrupting binding of ER to EREs represents an important potential application of the FAMA. HTS is facilitated by assays that show high well-to-well reproducibility, stability of the assay signal over time, and insensitivity to DMSO and other solvents. The FAMA demonstrated minimal variation in anisotropy across multiple wells, the assay was stable for more than 4 hours with ERα, ERβ, and PR bound to their response elements, and DMSO, ethanol, or methanol (at 5%-15% by volume) did not inhibit the assay (data not shown).
As proof-of-principle for use of the FAMA to identify inhibitors of ER-ERE binding, we tested a known inhibitor (21), the zinc chelator 1,10-phenanthroline. We observed a concentrationdependent inhibition of ERα binding to the cERE, with maximum inhibition of approximately 80% at 1000 μM 1,10-phenanthroline. Consistent with 1,10-phenanthroline's proposed function as a zinc chelator, inhibition was relieved by added zinc ( Figure 4A ). To determine if the FAMA could be used to identify novel inhibitors that might display selectivity for a specific receptor, we tested several zinc chelators not previously reported to disrupt steroid receptor binding to DNA response elements. PDTC did not inhibit binding of ERα or ERβ to the cERE at 400-1600 μM. The data for ERα and ERβ clustered closely around 100% binding, demonstrating the reproducibility of the FAMA. PDTC only inhibited PR binding to the PRE at 1200 and 1600 μM ( Figure 4D ). BPS and TPEN were more potent inhibitors, with BPS showing partial inhibition of binding of PR and ERβ to their DNAs at 100 μM and complete inhibition of binding of all three receptors to DNA by 800 μM of BPS and TPEN (Figure 4 , B and C). In general, the PR-PRE interaction was most sensitive to inhibition, followed by the ERβ-cERE interaction, with the ERα-cERE interaction being the least sensitive to inhibition.
The studies described in Figure 1 -4 were carried out in low-volume 96-well plates. Although the 20-μL sample volumes are similar to sample volumes normally used in the 384-well plates widely used in HTS, it was important to directly test the sensitivity of the FAMA in the 384-well format. We therefore determined that our assay had the requisite sensitivity for use with ER and PR in the 384-well format. An hERα-cERE binding curve generated using a 384-well microplate had a K d of approximately 4.5 nM, which was similar to the binding curve obtained using a 96-well plate ( Figure 5A ). To test the use of the 384-well microplate with inhibitors of DNA binding, we compared the binding of PR to the PRE in the presence of BPS in the 96-and 384-well microplates. We observed strong inhibition of binding in samples assayed in the 384-well microplates and in the 96-well microplates ( Figure 5B ). Because the anisotropy changes we observed using the 384-well plates were at least as large those observed using the 96-well plates ( Figure 5 ), the FAMA works well in screening using 384-well plates.
DISCUSSION
Our initial studies explored the flexibility and specificity of the FAMA. We observed ERα-cERE binding using RESEARCH REPORT different conditions, with K d values similar to those previously reported using EMSA. We also directly compared FAMA and EMSA in our testing of lower affinity, naturally occurring, imperfect EREs. Exhaustive DNA binding studies of imperfect EREs by EMSA or other techniques normally require either large amounts of ER or extensive, labor-intensive studies. With its low-volume reactions and multisample capability, the FAMA should prove ideal for the study of these EREs. Further, in contrast to EMSA, the FAMA is a true equilibrium method.
In living cells, steroid receptors must discriminate between bulk DNA and sequence-specific response elements. Because EMSA cannot easily measure the very weak low affinity interactions of steroid receptors with nonspecific DNA, this process has been difficult to study biochemically. In contrast, we show that in the low salt buffer without added poly dI:dC, the FAMA readily assesses nonspecific binding and should greatly facilitate research in this poorly understood area.
One demonstration of the FAMA's versatility is the ability to generate high-quality saturated binding curves with crude whole cell extracts containing hERα. Higher concentrations of control ER-negative cell extracts did produce a slight increase in anisotropy, presumably because of nonspecific binding to the cERE. For whole cell extracts that contain very low concentrations of receptor, optimization to reduce nonspecific binding in extracts from a particular source or preparation of nuclear extracts may be useful.
Another demonstration of the FAMA's versatility is the ability to generate high-quality saturated binding curves with steroid receptors whose sizes range from approximately 55 kDa for ERβ to approximately 120 kDa for PR-B. These studies represent the first fluorescence anisotropy analysis of binding of PR to a PRE. ER is generally considered to have higher affinity for the cERE than most other steroid receptors exhibit for their response elements. Because we effectively measured both PR-PRE interactions and binding of ER to lower affinity imperfect EREs, the FAMA should prove very useful in analyzing the lower affinity interactions of other steroid receptors with their response elements.
Our demonstration that binding of monoclonal antibodies to ER results in an approximate 50% increase in anisotropy compared to the ER-cERE complex strongly suggests that the FAMA can be used to analyze ERE-ER-coregulator interactions. The approximate 8-fold increase in size from the approximate 18 kDa fluorescent ERE alone to the approximate 150 kDa ERE-ERα complex produces a much larger change in anisotropy than the additional 3-fold change from approximately 150 kDa to the approximate 460 kDa ERE-ERα-Ab complex (assuming one molecule of monoclonal antibody is bound to each ER monomer in the ERE-ER dimer complex.)
Currently available small molecule therapeutics that modify steroid receptor action work by binding in the receptor's ligand binding pocket. The need for a new class of therapeutics was emphasized in a recent study of the development of anti-androgen resistant prostate cancers. These researchers concluded that development of new classes of small molecule antagonists that act outside of the receptor's ligand binding pocket would provide a new way to slow the development of tumor resistance (32) . Although agents that work by blocking binding of receptors to their response elements represent an obvious class of potential therapeutics, the absence of a suitable system for HTS has complicated the identification of these compounds. We began the process of developing the FAMA for HTS. We find that the FAMA assay is reproducible, stable, insensitive to inhibition by DMSO, and is well suited to the 384-well microplates often used in HTS. Of course, full-scale HTS using FAMA will require detailed consideration of the FAMA's precision, quality (Z′ factor; Reference 33), and issues of compound fluorescence (18) . However, our ability to assay different steroid receptors and to screen for compounds that work preferentially on a single receptor should minimize problems due to intrinsic fluorescence or the inhibition of receptor binding by interaction of compounds with the DNA. Compounds with intrinsic fluorescence or that fluoresce when bound to DNA, will fluoresce in the presence of the probe alone, and this can usually be corrected. Small molecules that inhibit receptor binding through an interaction with the DNA and not the receptor protein are unlikely to show sequence specificity and will therefore usually inhibit both ER and PR binding to their DNAs; consequently, these compounds would be unlikely to emerge as falsepositive candidates for receptor-selective agents. In the screen of several zinc chelators for inhibiting binding of ERs and PR to their response elements, we found that the PR was considerably more sensitive to inhibition than the ERs. These small-scale experiments illustrate the potential of FAMA for HTS applications focused on identification of small molecules that will selectively antagonize (or stimulate) the interaction of a specific steroid hormone receptor with its DNA response element.
